Navigation Links
NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
Date:1/12/2009

ans with regard to seeking potential development partners for its early-stage product pipeline. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, NeurogesX' product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; any regulatory approvals which are received may offer more limited indications than anticipated; physician or patient reluctance to use Qutenza or NGX-1998, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in, clinical development, obtaining regulatory approval, market acceptance and commercialization of NeurogesX' product candidates and the advantages of NeurogesX' product candidates over other pain therapies. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

    NeurogesX, Inc.
    Stephen Ghiglieri
    Chief Financial Officer
    (650) 358-3310

    The Ruth Group
    Stephanie Carrington / Sara Ephraim (investors)
    (646) 536-7017 / 7002
    scarrington@theruthgroup.com
    sephraim@theruthgroup.com

    Jason Rando (media)
    (646) 536-7025
    jrando@theruthgroup.com


'/>"/>
SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
2. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
3. NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
4. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
5. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
6. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
7. Pulmo BioTech Inc. Announces Dual Listing on Frankfurt Borse
8. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
9. Anesiva Announces FDA Approval of Supplemental New Drug Application to Expand Zingo(TM) Indication
10. ProUroCare Medical Inc. Announces Pricing of Equity Offering
11. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... has completed the sale to Galderma of all rights ... held by Valeant for $1.4 billion in cash, pursuant ... recently completed its acquisition of Galderma. ... products to a company that is firmly committed to ...
(Date:7/10/2014)... -- CVS Caremark Corporation (NYSE: CVS ) today ... dividend of $0.275 (27.5 cents) per share on the corporation,s ... to holders of record on July 21, 2014. ... to helping people on their path to better health as ... States . Through the company,s more than 7,600 CVS/pharmacy ...
(Date:1/15/2014)... 2014 Most osteoporosis patients want a choice in ... survey* sponsored by Mission Pharmacal Company. The survey, conducted ... online support community, revealed that 74 percent of osteoporosis ... a form other than a pill or a tablet. ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3
... Conn.--(BUSINESS WIRE)--Jun 11, 2007 - Neurogen,Corporation (Nasdaq: NRGN) ... studies for NG2-73, the Company's lead compound,for the ... SLEEP,2007 Annual Meeting of the Associated Professional Sleep ... studies,with NG2-73 in chronic insomnia patients are currently ...
... offers five questions to help women,learn about breast cancer ... – According to a new,GfK Roper Public Affairs survey ... the majority (76,percent) of women surveyed said they know ... unaware of the important recent,progress made in treatment. Fewer ...
Cached Medicine Technology:Neurogen Proprietary Insomnia Compound Data Presented at Associated,Professional Sleep Societies Annual Meeting 2Neurogen Proprietary Insomnia Compound Data Presented at Associated,Professional Sleep Societies Annual Meeting 3Neurogen Proprietary Insomnia Compound Data Presented at Associated,Professional Sleep Societies Annual Meeting 4Women Well-Informed About Breast Cancer, Yet Lacking Knowledge,About Current Treatments, New Survey Finds 2Women Well-Informed About Breast Cancer, Yet Lacking Knowledge,About Current Treatments, New Survey Finds 3
(Date:7/11/2014)... CT (PRWEB) July 11, 2014 ... the nation’s only non-profit dedicated exclusively to cell ... that Joshua Corday has joined the organization as ... fundraising professional with deep experience securing gifts and ... served as Annual Giving Director for NewYork Presbyterian ...
(Date:7/11/2014)... 11, 2014 Global enterprises today are ... outsource day-to-day management activities. Managed services offer these global ... The economic slowdown resulted into rising operational costs to ... is considered to be the global market driver for ... The global managed services market is estimated to grow ...
(Date:7/11/2014)... Presently, disposable medical suppliers call for the ... segment. During the past two decades, the world market ... average 12.5% per year), primarily owing to the importance ... is the largest market for disposable medical supplies in ... second position is held by Europe with a 29% ...
(Date:7/11/2014)... PROVIDENCE, R.I. -- Researchers from The Miriam ... under age 65 have significantly higher rates of ... with mobility impairments were less likely to attempt ... quit-smoking treatments may not be sufficient for this ... online in advance of print in the ...
(Date:7/11/2014)... kind has found that organic foods and crops ... counterparts, including more antioxidants and fewer, less frequent ... unprecedented 343 peer-reviewed publications comparing the nutritional quality ... including fruits, vegetables, and grains. The study team ... organic and non-organic foods. , "Science marches ...
Breaking Medicine News(10 mins):Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 2Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 3Health News:Miriam Hospital study examines smoking prevalence 2Health News:Major study documents nutritional and food safety benefits of organic farming 2Health News:Major study documents nutritional and food safety benefits of organic farming 3
... INDIANAPOLIS Technologies for rapid detection of bacterial ... supply. Researchers from the School of ... the Bindley Bioscience Center at Purdue University have ... classification of harmful bacteria in food. The investigators ...
... in the Oct. 15 issue of the Journal of ... a much higher prevalence and risk of restless legs syndrome ... may improve sleep and quality of life in people with ... syndrome was about 10 times higher in the fibromyalgia group ...
... prodigious precursors of all the tissues in our body, ... unfortunately, cancer. Now research from Rockefeller University shows that ... live for too long, can increase the odds of ... cell death in precursor cells for blood, or hematopoietic ...
... a class of drugs known as beta blockers have been ... by decreasing the cardiac workload and oxygen demand on the ... Heart Journal , Northwestern Medicine cardiologist Jeffrey J. Goldberger found ... enough dose of these drugs, which can put their recovery ...
... Reporter , THURSDAY, Oct. 14 (HealthDay News) -- Only one ... recommended colon cancer screening guidelines, a new report finds. ... while the remaining 40 percent don,t follow guidelines for any ... to be done to understand how to improve colorectal cancer ...
... Two years ago, a study by University of North ... drug called ondansetron helps reduce vomiting, the need for ... gastroenteritis. Now a new economic analysis led by ... assistant professor of pediatrics at UNC, concludes that routinely ...
Cached Medicine News:Health News:Eat safer: Novel approach detects unknown food pathogens 2Health News:Study finds a high rate of restless legs syndrome in adults with fibromyalgia 2Health News:Gene identified that prevents stem cells from turning cancerous 2Health News:Gene identified that prevents stem cells from turning cancerous 3Health News:Low beta blocker dose can put patients at risk for subsequent heart attacks 2Health News:Most Doctors Don't Follow Colon Cancer Screening Guidelines 2Health News:Most Doctors Don't Follow Colon Cancer Screening Guidelines 3Health News:Anti-vomiting drug could prevent thousands of hospitalizations, save millions of dollars 2
... especially suited for cell analysis and ... allows to analyze scatter signals in ... channels. Data acquisition, analysis, and real-time ... PC employing Partec DPAC software, built-in ...
Dual laser powered flow cytometer...
... The IMMULITE 2000, a continuous ... throughput of 200 tests per hour, ... efficiency and consolidation in medium- and ... package, with its self-explanatory graphical user ...
... Vidas is an automated, ... designed testing device stores the ... thus optimizing the cost-per-patient result. ... minimum maintenance, ease of use ...
Medicine Products: